Improved outcome for AML patients over the years 2000-2014

Area of Science:

• Hematology
• Oncology
• Clinical Research

Background:

• Recent registry studies suggest improved survival in younger acute myeloid leukemia (AML) patients.
• The underlying reasons for this survival improvement in AML patients remain unclear.

Purpose of the Study:

• To analyze the therapeutic course and outcomes of acute myeloid leukemia (AML) patients treated with intensive chemotherapy.
• To identify factors contributing to survival improvements in younger and older AML patients over time.

Main Methods:

• Retrospective analysis of 976 acute myeloid leukemia (AML) patients treated between 2000 and 2014.
• Evaluation of treatment trends, including allogeneic and autologous stem cell transplantation, and their association with survival outcomes.
• Multivariate analysis to assess the impact of treatment period and patient characteristics on survival.

Main Results:

• Younger AML patients (513) showed no significant changes in response rates, relapse, or non-relapse mortality over time.
• Overall survival significantly improved for younger AML patients, particularly in the 2010-2014 period, independent of stem cell transplantation.
• Older AML patients (463) demonstrated improved response and survival in the 2010-2014 period, specifically those with white blood cell counts >50 Giga/L (hyperleukocytic).

Conclusions:

• Survival improvements in younger acute myeloid leukemia (AML) patients are attributed to progress across all therapeutic phases.
• The recent therapeutic period (2010-2014) has significantly benefited older AML patients with hyperleukocytosis.
• Further research is needed to fully elucidate the specific advances driving these observed survival gains in AML.